ReviewClinical rheumatology2026
Abatacept in biologic-refractory juvenile idiopathic arthritis-associated uveitis: a case-based review.
Review in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMonoclonal anti-tumor necrosis factor (anti-TNF) agents have substantially improved the management of juvenile idiopathic arthritis (JIA)-associated uveitis. However, some patients remain refractory despite multiple biologic therapies. We aimed to evaluate the outcomes of abatacept in patients with chronic JIA-associated uveitis refractory to synthetic DMARDs, anti-TNF agents, and tocilizumab at a tertiary referral center and to review the available pediatric literature.
methodsThis retrospective observational series included patients with chronic JIA-associated uveitis treated with abatacept after inadequate response to anti-TNF agents and tocilizumab. Ocular outcomes included achievement of inactive uveitis, discontinuation of topical corticosteroid therapy, and adverse events. Articular disease activity and additional treatments required during abatacept therapy were also recorded. A systematic review of the pediatric literature on abatacept treatment for JIA-associated uveitis was additionally performed.
resultsSeven patients were included. By month 3, five patients achieved inactive uveitis and discontinued topical corticosteroid therapy, whereas two patients showed no ocular response. Among the five responders, one discontinued abatacept at month 9 because of a skin infection requiring hospitalization and intravenous antibiotics, while the remaining four maintained inactive uveitis through month 12. Articular responses were less consistent, and four patients required additional treatment for arthritis during follow-up. The literature review identified 15 studies including 95 abatacept-treated patients, with reported remission rates ranging from 0 to 100%.
conclusionAbatacept may be a useful therapeutic option for JIA-associated uveitis refractory to anti-TNF agents and tocilizumab. Ocular response may occur despite persistent or recurrent articular activity, suggesting that ocular and articular outcomes should be assessed separately. Larger prospective studies are needed to better define the role of abatacept in refractory JIA-associated uveitis.
Indexed as
Identifiers
42836943What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.